Kepler Capital Markets reiterated their buy rating on shares of AstraZeneca (LON:AZN) in a report issued on Thursday, November 22nd. Kepler Capital Markets currently has a GBX 6,100 ($79.71) price objective on the biopharmaceutical company’s stock.

A number of other research firms also recently issued reports on AZN. BNP Paribas set a GBX 6,500 ($84.93) price objective on shares of AstraZeneca and gave the stock a buy rating in a report on Tuesday, September 11th. JPMorgan Chase & Co. set a GBX 6,500 ($84.93) price objective on shares of AstraZeneca and gave the stock a buy rating in a report on Tuesday, September 25th. Barclays set a GBX 6,500 ($84.93) price objective on shares of AstraZeneca and gave the stock a buy rating in a report on Friday, July 27th. Goldman Sachs Group set a GBX 4,080 ($53.31) price objective on shares of AstraZeneca and gave the stock a sell rating in a report on Friday, November 16th. Finally, Jefferies Financial Group set a GBX 6,200 ($81.01) price objective on shares of AstraZeneca and gave the stock a neutral rating in a report on Thursday, August 16th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus price target of GBX 5,927.44 ($77.45).

LON AZN traded down GBX 28 ($0.37) during mid-day trading on Thursday, hitting GBX 5,927 ($77.45). The company’s stock had a trading volume of 2,638,281 shares, compared to its average volume of 2,310,000. AstraZeneca has a twelve month low of GBX 4,260 ($55.66) and a twelve month high of GBX 5,520 ($72.13).

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Article: How Does the Quiet Period Work?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.